Investors look for better efficacy from safe cancer immunotherapies
This article was originally published in Scrip
Executive Summary
Company executives and biotech investors are very grateful for the way that Seattle-based Dendreon has paved the way for other cancer vaccines and immunotherapies. While it is still uncertain that the Provenge vaccine for metastatic castrate-resistant prostate cancer and its $93,000 price tag will ever be seen as a significant medical intervention or a commercial success, Dendreon's pioneering journey through both the technical and regulatory space is appreciated widely.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.